Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaam7577. doi: 10.1126/scitranslmed.aam7577.

2.

Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.

Samson A, Bentham MJ, Scott K, Nuovo G, Bloy A, Appleton E, Adair RA, Dave R, Peckham-Cooper A, Toogood G, Nagamori S, Coffey M, Vile R, Harrington K, Selby P, Errington-Mais F, Melcher A, Griffin S.

Gut. 2018 Mar;67(3):562-573. doi: 10.1136/gutjnl-2016-312009. Epub 2016 Nov 15.

3.

Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.

Parrish C, Scott GB, Migneco G, Scott KJ, Steele LP, Ilett E, West EJ, Hall K, Selby PJ, Buchanan D, Varghese A, Cragg MS, Coffey M, Hillmen P, Melcher AA, Errington-Mais F.

Leukemia. 2015 Sep;29(9):1799-810. doi: 10.1038/leu.2015.88. Epub 2015 Mar 27.

4.

Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma.

Jebar AH, Errington-Mais F, Vile RG, Selby PJ, Melcher AA, Griffin S.

J Gen Virol. 2015 Jul;96(Pt 7):1533-50. doi: 10.1099/vir.0.000098. Epub 2015 Feb 23. Review.

5.

BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.

Roulstone V, Pedersen M, Kyula J, Mansfield D, Khan AA, McEntee G, Wilkinson M, Karapanagiotou E, Coffey M, Marais R, Jebar A, Errington-Mais F, Melcher A, Vile R, Pandha H, McLaughlin M, Harrington KJ.

Mol Ther. 2015 May;23(5):931-942. doi: 10.1038/mt.2015.15. Epub 2015 Jan 26.

6.

Viral warfare! Front-line defence and arming the immune system against cancer using oncolytic vaccinia and other viruses.

Dave RV, Jebar AH, Jennings VA, Adair RA, West EJ, Errington-Mais F, Toogood GJ, Melcher AA.

Surgeon. 2014 Aug;12(4):210-20. doi: 10.1016/j.surge.2014.01.001. Epub 2014 Feb 4. Review.

PMID:
24502935
7.

Applications of coxsackievirus A21 in oncology.

Bradley S, Jakes AD, Harrington K, Pandha H, Melcher A, Errington-Mais F.

Oncolytic Virother. 2014 Apr 10;3:47-55. doi: 10.2147/OV.S56322. eCollection 2014. Review.

8.

Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.

Jennings VA, Ilett EJ, Scott KJ, West EJ, Vile R, Pandha H, Harrington K, Young A, Hall GD, Coffey M, Selby P, Errington-Mais F, Melcher AA.

Int J Cancer. 2014 Mar 1;134(5):1091-101. doi: 10.1002/ijc.28450. Epub 2013 Sep 18.

9.

Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells.

Adair RA, Scott KJ, Fraser S, Errington-Mais F, Pandha H, Coffey M, Selby P, Cook GP, Vile R, Harrington KJ, Toogood G, Melcher AA.

Int J Cancer. 2013 May 15;132(10):2327-38. doi: 10.1002/ijc.27918. Epub 2012 Nov 26.

10.

Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.

Hall K, Scott KJ, Rose A, Desborough M, Harrington K, Pandha H, Parrish C, Vile R, Coffey M, Bowen D, Errington-Mais F, Melcher AA.

Biores Open Access. 2012 Jan;1(1):3-15. doi: 10.1089/biores.2012.0205.

11.

Measles virus causes immunogenic cell death in human melanoma.

Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, Peach H, Phillips RM, Bond J, Pandha H, Harrington K, Vile R, Russell S, Selby P, Melcher AA.

Gene Ther. 2013 Jan;20(1):7-15. doi: 10.1038/gt.2011.205. Epub 2011 Dec 15.

12.

Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles.

Win SJ, McMillan DG, Errington-Mais F, Ward VK, Young SL, Baird MA, Melcher AA.

Br J Cancer. 2012 Jan 3;106(1):92-8. doi: 10.1038/bjc.2011.538. Epub 2011 Dec 1.

13.

Recent clinical experience with oncolytic viruses.

Donnelly OG, Errington-Mais F, Prestwich R, Harrington K, Pandha H, Vile R, Melcher AA.

Curr Pharm Biotechnol. 2012 Jul;13(9):1834-41. Review.

PMID:
21740364
14.

Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.

Ilett EJ, Bárcena M, Errington-Mais F, Griffin S, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Limpens RW, Mommaas M, Hoeben RC, Vile RG, Melcher AA.

Clin Cancer Res. 2011 May 1;17(9):2767-76. doi: 10.1158/1078-0432.CCR-10-3266. Epub 2011 Mar 9.

Supplemental Content

Loading ...
Support Center